Immix Biopharma · pitchdeck
Immix Biopharma | Investor Presentation Deck | 64 slides
64 pages · 5 arc beats · 3 loops
Immix Biopharma | Investor Presentation Deck | 64 slides
Immix Biopharma · 2023-11 arc beats above · slides in the middle · loops below · scroll → 3 LOOPS
15101520253035404550556064
Deck intelligence map
5 coverage by narrative range · generated from this deck JSON
Narrative range 22 total
Metadata
Components
Metrics
Tools
Frameworks
Beats
Loops
Problem 1 slides 100% 1/1 slides 100% 1/1 slides · 3 hits — 0/1 slides
100% 1/1 slides 100% 1/1 slides 100% 1/1 slides · 2 hits 100% 1/1 slides Solution 5 slides 100% 5/5 slides 100% 5/5 slides · 25 hits — 0/5 slides
60% 3/5 slides 80% 4/5 slides 100% 5/5 slides · 6 hits 20% 1/5 slides Market Sizing 6 slides 100% 6/6 slides 100% 6/6 slides · 33 hits — 0/6 slides
— 0/6 slides
83.3% 5/6 slides 100% 6/6 slides · 10 hits — 0/6 slides
Traction 5 slides 100% 5/5 slides 100% 5/5 slides · 23 hits — 0/5 slides
40% 2/5 slides 80% 4/5 slides 100% 5/5 slides — 0/5 slides
Roadmap 5 slides 100% 5/5 slides 100% 5/5 slides · 21 hits — 0/5 slides
— 0/5 slides
100% 5/5 slides 100% 5/5 slides · 9 hits — 0/5 slides
Slide inventory
64 every slide · same image gating as the playbook
04
The slide uses a structured grid layout to categorize team members into three distinct groups: Leadership, Board of Directors, and Scientific Advisory Board.other
05
The slide uses a cause-and-effect structure to map platform capabilities to strategic outcomes.present_solution
Open slide detailBeat · Solution
06
Uses a human anatomy diagram to map therapeutic areas to diseases; includes a pyramid at the bottom highlighting 'Other diseases' and the key differentiator 'Ovpresent_solution
Open slide detailBeat · Solution
07
Includes a cartoon illustration of a cell/virus character.frame_problem
08
The slide uses a structural diagram to highlight the specific modifications (COBRA Binder) that differentiate NXC-201 from the reference therapy.present_solution
Open slide detailBeat · Solution
09
The slide uses a diagram to map specific protein domains to their functional benefits.present_solution
Open slide detailBeat · Solution
10
The slide uses authority-citation to validate the mechanism of ITAM modification and degradation.present_solution
11
The slide uses a combination of bar charts for preclinical cytokine release and a table for clinical outcomes to demonstrate the competitive advantage of NXC-20compare_peers
12
The slide compares HSL (Heavy-chain-led) vs LSH (Light-chain-led) configurations, demonstrating superior performance for HSL.present_solution
14
The slide explicitly notes that this is a cross-trial comparison and not a head-to-head study.compare_peers
15
The slide uses a biological structural diagram to illustrate the proprietary nature of the COBRA binding domain compared to standard CAR-T constructs.present_solution
16
Includes comparative data points for transduction efficiency and experimental data for signaling and exhaustion.present_solution
17
The slide uses a multi-panel line chart to compare clinical outcomes across three different therapies.compare_peers
18
The chart demonstrates the mechanism of action: rapid cell expansion followed by clearance within 30 days, correlating with disease marker reduction.show_traction
Open slide detailBeat · Traction
19
The slide uses a causal chain framework to link cellular pathology to systemic organ damage.frame_problem
Open slide detailBeat · Traction
20
The slide uses a grouped bar chart format to compare clinical outcomes across different therapeutic agents.compare_peers
Open slide detailBeat · Traction
21
The slide uses a table to contrast treatment efficacy and patient growth across disease stages.compare_peers
Open slide detailBeat · Traction
22
The slide explicitly notes that these are cross-trial comparisons and not head-to-head results.compare_peers
Open slide detailBeat · Traction
23
Includes FDA approval precedents as a footnote to justify the clinical strategy.plan_implementation
Open slide detailBeat · Roadmap
24
Uses a visual icon-grid to represent market expansion.size_opportunity
Open slide detailBeat · Market Sizing
25
Includes detailed clinical trial citations in the footer.show_traction
Open slide detailBeat · Market Sizing
26
The slide uses a two-column layout to separate milestones by drug candidate.plan_implementation
Open slide detailBeat · Market Sizing
27
The slide uses a standard pharmaceutical pipeline table format, categorizing by clinical vs preclinical status and highlighting specific regulatory designationsshow_traction
Open slide detailBeat · Market Sizing
28
Includes a comparative table of clinical outcomes (ORR/CR) for NXC-201 vs competitors.size_opportunity
Open slide detailBeat · Market Sizing
29
The slide uses a visual wave/area chart metaphor to represent market segments and their respective valuations.size_opportunity
Open slide detailBeat · Market Sizing
31
The slide uses a red dashed box to highlight the primary efficacy metrics for comparison.compare_peers
32
The chart uses a grouped bar structure to compare NXC-201 (green) against other therapies (blue/red) categorized by prior BCMA treatment status.compare_peers
33
The table compares NXC-201 against various CAR-T therapies, highlighting patient characteristics, efficacy (ORR, CR), and safety (ICANS, CRS) metrics.compare_peers
34
The slide uses a side-by-side comparison of two disease indications, showing clinical results, relevant competitor benchmarks, and market size.show_traction
35
The chart demonstrates deepening clinical response over time for NXC-201 therapy.show_traction
36
The table displays clinical trial data for NXC-201, specifically focusing on safety profiles and management interventions.analyze_data
37
The table highlights specific clinical safety metrics including onset and duration for CRS and ICANS, as well as the use of Tocilizumab and Dexamethasone.compare_peers
38
The slide uses a step-wise diagram to illustrate dose escalation in a clinical trial setting.plan_implementation
39
The slide features a scientific illustration of cellular structures, likely representing the drug's mechanism of action or target environment.transition
40
Includes scientific diagrams of molecular pathways, penetration depth charts, and efficacy metrics.present_solution
41
Slide contains three distinct charts comparing IMX-110 against standard of care in mouse models.show_traction
42
Includes a process flow diagram illustrating the mechanism of action of IMX-110 in tumor microenvironments.illustrate_case
43
Includes survival curves (Kaplan-Meier style), median survival bar charts, and bioluminescence imaging of tumor activity.show_traction
45
The slide compares sarcoma patients against non-sarcoma patients using line charts for lesion size change and a bar chart for best percentage change.show_traction
46
The bubble chart maps mPFS against patient treatment history; the table highlights poor outcomes and high toxicity across lines of therapy.frame_problem
48
Shows two parallel clinical development tracks: monotherapy and combination with tislelizumab.plan_implementation
50
The slide uses a process-flow style layout to connect the platform's core capabilities to specific product outputs.present_solution
51
The slide uses a '3 Pillars' framework to explain the platform foundation, followed by a product-specific breakdown.present_solution
52
Includes a comparative size diagram of the drug vs IgG antibody and a Kaplan-Meier survival curve.present_solution
53
Includes two distinct sets of preclinical charts (tumor volume and survival curves) with detailed methodology in footnotes.show_traction
54
Includes multiple citations and diagrams illustrating the mechanism of action and clinical results.present_solution
55
The slide uses a numbered list format to present key value propositions.summarize
57
The slide uses a side-by-side comparison structure to explain two distinct proprietary platforms.present_solution
58
The process flow is non-linear, moving left-to-right on the top row (1-5) and right-to-left on the bottom row (6-10).plan_implementation
59
Highlights NXC-201's lower fludarabine dose and compares infusion timing across therapies.compare_peers
60
The table compares four different therapies across four criteria categories: Prior lines of therapy, Toxicity recovery, ECOG, and Measurable disease.compare_peers
61
The slide highlights that NXC-201 has no exclusion for prior BCMA therapy, unlike the other listed treatments.compare_peers
62
The slide uses a combination of expert testimonials and a comparative clinical trial table to validate the outpatient therapy thesis.show_traction
63
The slide uses a bar chart to contrast the combined sales of two groups of oncology drugs.size_opportunity
64
The slide uses a bar-grouped chart format to highlight the efficacy gap between established treatments and placebo.compare_peers